TD Cowen analyst Dan Brennan raised the firm’s price target on Exact Sciences (EXAS) to $86 from $82 and keeps a Buy rating on the shares. The firm said the final Medicare price for Cologuard Plus is better than expected leading the firm to raise its estimates.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Closing Bell Movers: Semtech rises, Zoom falls after earnings
- Exact Sciences to present 10 abstracts on Precision Oncology portfolio at SABCS
- Exact Sciences to present abstracts on multi-cancer early detection test
- Exact Sciences price target lowered to $75 from $85 at Piper Sandler
- Exact Sciences price target lowered to $70 from $75 at Wells Fargo